Neisvac-C

Tetanus toxoid, algeldrate, Neisseria meningitidis group C (strain C11) polysaccharide (de‑O‑acetylated), the active ingredient in Neisvac‑C, is a vaccine presented as an injectable solution for intramuscular use. It is employed to induce protective immunity against tetanus and against meningococcal disease caused by Neisseria meningitidis group C in individuals requiring immunisation.

GNH USA supplies Neisvac‑C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides cold‑chain logistics for biologic products.

Neisvac‑C is a tetanus and meningococcal conjugate vaccine used in immunisation programmes to prevent specific bacterial infections. - Tetanus: provides active immunity that protects against tetanus toxin in individuals of all ages. - Meningococcal group C disease: induces antibodies against the polysaccharide capsule of Neisseria meningitidis group C, reducing risk of invasive meningitis. - Routine immunisation schedules: can be incorporated into childhood or adult booster schedules to maintain protective antibody levels.

Injection of Neisvac‑C may be associated with local and systemic reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: mild soreness at the site of administration. - Redness or swelling: localized erythema or edema. - Low‑grade fever: temperature rise up to 38 °C within 24 hours. - Headache: mild to moderate headache following vaccination. - Fatigue: transient tiredness lasting a day or two.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder potentially triggered post‑vaccination. - Seizures: uncommon occurrence, especially in individuals with pre‑existing neurologic conditions. - Severe local reaction: extensive swelling or necrosis at injection site. - Thrombotic events: very rare clotting disorders reported in isolated cases.

Before administering Neisvac‑C, healthcare professionals should observe several precautionary measures to ensure safety. - Allergy assessment: verify no known hypersensitivity to tetanus toxoid, algeldrate or meningococcal polysaccharide. - Acute illness: postpone vaccination in persons with moderate or severe febrile illness until recovery. - Prior reaction: avoid repeat dosing in individuals who experienced a severe allergic response to a previous dose. - Pregnancy considerations: use only if the benefit outweighs potential risk and after medical consultation. - Immunocompromised patients: anticipate possible reduced antibody response and monitor serology. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines can interact with other medicines or biologics, affecting efficacy or safety.

Major Interactions (Avoid): - Live vaccines: avoid simultaneous administration with live attenuated vaccines to prevent interference. - Immunoglobulin therapy: concurrent use may diminish the immune response to the vaccine. - Blood products: transfusion within 48 hours may reduce vaccine effectiveness.

Moderate Interactions (Monitor Closely): - Antipyretics: analgesics such as acetaminophen may mask fever, a sign of reaction. - Immunosuppressive drugs: may lower antibody production, requiring serological monitoring. - Corticosteroids: high‑dose steroids can attenuate the immune response, consider timing of vaccination.